Androgens and estrogens in benign prostatic hyperplasia: past, present and future. - sprookjes - yvandenbroek - TriplyDB

Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

http://www.wikidata.org/entity/Q35231660

about

Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia Testosterone and benign prostatic hyperplasia Xenotransplantation models to study the effects of toxicants on human fetal tissues Bisphenol a and reproductive health: update of experimental and human evidence, 2007-2013 Towards engineering hormone-binding globulins as drug delivery agents Testosterone and 17β-estradiol induce glandular prostatic growth, bladder outlet obstruction, and voiding dysfunction in male mice Aberrant Transforming Growth Factor-β Activation Recruits Mesenchymal Stem Cells During Prostatic Hyperplasia.Compounds from Cynomorium songaricum with Estrogenic and Androgenic Activities Suppress the Oestrogen/Androgen-Induced BPH Process Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues.Personalized medicine for the management of benign prostatic hyperplasia Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network Safety and tolerability of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN).Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.Bisphenol A exposure during adulthood alters expression of aromatase and 5α-reductase isozymes in rat prostate Maturation of the developing human fetal prostate in a rodent xenograft model.The in vitro and in vivo anti-cancer activities of a standardized quassinoids composition from Eurycoma longifolia on LNCaP human prostate cancer cells Increased infiltrated macrophages in benign prostatic hyperplasia (BPH): role of stromal androgen receptor in macrophage-induced prostate stromal cell proliferation Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development.Activation of innate anti-viral immune response genes in symptomatic benign prostatic hyperplasia Estrogens and Male Lower Urinary Tract Dysfunction The Predominant Proteins that React to the MC-20 Estrogen Receptor Alpha Antibody Differ in Molecular Weight between the Mammary Gland and Uterus in the Mouse and Rat.Action Mechanism of Ginkgo biloba Leaf Extract Intervened by Exercise Therapy in Treatment of Benign Prostate Hyperplasia.Effects of Transdermal Testosterone Gel or an Aromatase Inhibitor on Prostate Volume in Older Men In Utero and Lactational TCDD Exposure Increases Susceptibility to Lower Urinary Tract Dysfunction in Adulthood Differential expression of androgen, estrogen, and progesterone receptors in benign prostatic hyperplasia Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase.Alcohol exposure in utero increases susceptibility to prostate tumorigenesis in rat offspring.Renal capsule xenografting and subcutaneous pellet implantation for the evaluation of prostate carcinogenesis and benign prostatic hyperplasia.Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions.A possible relationship between serum sex hormones and benign prostatic hyperplasia/lower urinary tract symptoms in men who underwent transurethral prostate resection.CD8+ T cells promote proliferation of benign prostatic hyperplasia epithelial cells under low androgen level via modulation of CCL5/STAT5/CCND1 signaling pathway.Selective estrogen receptor modulators for BPH: new factors on the ground.Benign prostatic hyperplasia: a new metabolic disease?Hormonal manipulation of lower urinary tract symptoms secondary to benign prostatic obstruction.Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer.De novo steroid biosynthesis in human prostate cell lines and biopsies.Endocrine control of benign prostatic hyperplasia.Opposite effects of tamoxifen on metabolic syndrome-induced bladder and prostate alterations: a role for GPR30/GPER?Female prostate: historical, developmental, and morphological perspectives.

P2860

Q24186736-5A7D1351-0466-4205-9147-69607BC0175C Q26741226-971A03D3-7A63-480B-BBAD-A0BDC5B6C1E5 Q26863719-D83FC46E-6036-4959-9FB7-9C443B0EAE83 Q27013024-9AB2E922-E71B-490F-8F1E-9F1E5C7A0BED Q28391779-EA4705FB-D780-4BCD-A5FF-D75357E97E3C Q28545213-377CE349-6ADD-4075-A325-83FB20427969 Q30525673-F164A0F9-F806-45B2-99C2-C0A68563A931 Q33722426-3612C666-619F-4276-8211-0CD856961793 Q33735698-D1F51B4F-7EB3-4DEF-89C8-737CCC665C5A Q34064040-69C49D4B-C861-459B-B76C-7CF847E46458 Q34084593-74717E00-5D52-4069-81FE-784A07462112 Q34163024-C0C196A4-6FA3-45A8-A72F-4FAF6AF63DE9 Q34323757-75CFE0EF-5B43-43B7-801F-425D8F013254 Q34529072-27303910-7F87-46A0-9CB4-F967F137EFEA Q34584590-ADBDDAB5-795B-4A4D-80C8-741F882D406A Q34987740-E946B1E0-A0EC-4308-A24E-1F5FF69109A9 Q35234916-57515BC7-2168-4336-80CF-EB2E9F1B0FAE Q36003050-F07D8128-9A35-4386-A28D-DA35D8DA1260 Q36279487-498706D8-D415-4F06-BE92-98E01E3F0222 Q36331201-C9F85335-2A31-426B-A69C-CF42AA570A2B Q36518535-EB9DE266-5CFF-4E5B-B8A9-A4C138C4C3CF Q36735733-E1C4A8BD-D964-48F6-9D51-A9A811524E6C Q36838223-E4B70C5F-20EF-40EE-A06E-87BA854556E6 Q36935566-56BD5464-0B48-4F04-95FB-B23B2508E1B3 Q36987154-C9E175A4-1904-40A3-AE0B-1A5ACDFC9B67 Q37161245-F98870E5-95B1-463D-AEE8-1E1AD646952F Q37195621-139C50A1-04DE-458E-A707-E9DA12830148 Q37265869-5C8106C0-7549-40C9-9A2D-F2F723CE0C2A Q37377598-37E29FE6-2F28-4E0F-8969-87AFC31B87E8 Q37618958-EE8D5ED1-EA6A-4A4C-A6E8-C53158327ED2 Q37644679-69EAA056-32ED-4527-90FF-437DFAAAB7C4 Q37652222-75C5F66F-89E4-4C6E-994C-3D301F6B6D97 Q38115066-07E1E81D-9C5D-4FA8-86DA-21E1B0FC83F9 Q38181426-E0F51DDE-C4F8-44B4-A5B5-9963EE43A41C Q38205422-3CB379B6-8327-4A6C-A61C-6E697A9C53F8 Q38272331-D516A2A7-A5AA-4392-BFD4-9ED2256F9F6F Q38796893-2F8DA8F4-5036-4633-A224-74ECCEBE164F Q38811041-32F8E6EB-E575-4059-8CF0-C0D0106715CE Q39095837-D97D6913-EF52-4CA8-92E2-8653C1FD5F4F Q39161021-CBF99454-E4DB-4956-8AB5-75BFE445EDF2

P2860

Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

http://www.wikidata.org/entity/Q35231660

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

@ast

Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

@en

type

label

Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

@ast

Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

@en

prefLabel

Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

@ast

Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

@en

P1433

Q35231660-8683C90E-4AEE-426B-9CF9-F5D9F1FD7CA0

P1476

Q35231660-DD0276C5-46C7-461B-8C1E-513159BAC940

P2093

Q35231660-67E4FC25-18D4-4076-895B-A105C05B88C3

Q35231660-ABFADAC1-14A0-4BF1-871B-084B0AB267FD

P2860

Q35231660-0111760C-0BE1-422E-A99B-ED252FEC98D1

Q35231660-027EE57E-2238-4646-AA4E-EA25F44F093B

Q35231660-031B975D-F719-435F-8EC2-575686908BD2

Q35231660-0382739D-3AE1-44B1-9D91-A296C979A99C

Q35231660-05E3CE7D-C194-46BF-9765-54634B3D0613

Q35231660-06766A71-441A-470F-876D-85ABCE3B432D

Q35231660-0678CDCE-24FA-40C9-8BC7-0580A0261331

Q35231660-067F0885-1C2B-4063-A5AE-490C35FB6E57

Q35231660-08104E93-3F9E-4613-815A-D91E87E23C5A

Q35231660-0C652C03-DD52-4DE6-961F-8233DE84235F

P304

Q35231660-6267CC23-C42C-4296-9DB0-9242C919F791

P31

Q35231660-28BB3E42-3F0A-4540-8429-40624DEFEEA4

P356

Q35231660-C8F1C2A6-7316-4803-A02E-00505604E5A2

P433

Q35231660-017EB2A7-EC7E-4BB0-B769-1F5234530B83

P478

Q35231660-E805BCBC-0F69-4DD7-A1A2-C7887C8D50D0

P577

Q35231660-896D1D06-F406-4D8F-9C89-B542ACD93E7B

P698

Q35231660-C6CDB2A2-93F5-48CF-A742-07851AE04CA8

P932

Q35231660-77615B32-6CE1-4FF1-AA5A-74E47B92DEDF

P356

J.DIFF.2011.04.006

P1433

Differentiation

P1476

Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

@en

P2093

Tristan M Nicholson

http://www.w3.org/2001/XMLSchema#string

William A Ricke

http://www.w3.org/2001/XMLSchema#string

P2860

Serenoa repens for benign prostatic hyperplasia

Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer

Repressors of androgen and progesterone receptor action

Estrogenic chemicals in plastic and oral contraceptives disrupt development of the fetal mouse prostate and urethra.

An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth

Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4

Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

Beta-sitosterols for benign prostatic hyperplasia

Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis

P304

184-199

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.DIFF.2011.04.006

http://www.w3.org/2001/XMLSchema#string

P433

4-5

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21620560

http://www.w3.org/2001/XMLSchema#string

P932

3179830

http://www.w3.org/2001/XMLSchema#string